Clinical trials: Primary IgA Nephropathy
IgA Nephropathy (IgAN)
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of…
- Trial name
- LUMINA IgAN (NCT07850752)
- Testing
- zigakibart, atrasentan
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals
Primary IgA Nephropathy
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
- Trial name
- NCT04291781
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RemeGen Co., Ltd.
Primary IgA Nephropathy
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials.
- Trial name
- NCT04557462
- Testing
- LNP023
- Where
- 161 sites in United States, Argentina and 34 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Disease, Glomerulonephritis
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
This study will have two parts. The main aims are to: check the side effects from mezagitamab. check for long-term side effects from mezagitamab.
- Trial name
- NCT05174221
- Testing
- Mezagitamab
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 17 people
- Sponsor
- Takeda
Primary IgA Nephropathy
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN).
- Trial name
- NCT07354932
- Testing
- SHR-2173 injection
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Primary IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high…
- Trial name
- IMAGINATION (NCT05797610)
- Testing
- Sefaxersen (RO7434656)
- Where
- 171 sites in United States, Argentina and 19 more
- Volunteers
- 459 people
- Sponsor
- Hoffmann-La Roche
Primary IgA Nephropathy
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to evaluate the effect of IONIS-FB-LRx on plasma…
- Trial name
- NCT04014335
- Testing
- IONIS-FB-LRx
- Where
- 7 sites in Australia, Canada and 2 more
- Volunteers
- 23 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Primary IgA Nephropathy
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with…
- Trial name
- NCT05799287
- Testing
- Telitacicept
- Where
- 101 sites in China
- Volunteers
- 318 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Immunoglobulin a Nephropathy
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
- Trial name
- NCT06635772
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hansoh BioMedical R&D Company
IgA Nephropathy
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d.
- Trial name
- APPLAUSE-IgAN (NCT04578834)
- Testing
- LNP023
- Where
- 177 sites in United States, Argentina and 33 more
- Volunteers
- 518 people
- Sponsor
- Novartis Pharmaceuticals
Primary IgA Nephropathy
Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy
NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.
- Trial name
- NCT06982040
- Testing
- NTQ5082 capsules 100 mg, NTQ5082 capsules 200 mg, NTQ5082 capsules 300 mg
- Volunteers
- 80 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
IgA Nephropathy (IgAN)
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and safety of MY008211A in IgAN patients
- Trial name
- NCT06687174
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
IgA Nephropathy
Study of CM313 in Subject With IgA Nephropathy
This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK)…
- Trial name
- NCT06830395
- Testing
- CM313
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Keymed Biosciences Co.Ltd
IgA Nephropathy (IgAN)
SLN12140 in Adult Participants With IgA Nephropathy in China
This study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of…
- Trial name
- NCT07553494
- Testing
- SLN12140
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Linno Pharmaceuticals, Inc.
IgA Nephropathy
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16…
- Trial name
- NefXtend (NCT06712407)
- Testing
- TARPEYO®
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Calliditas Therapeutics AB
Immunoglobulin A Nephropathy (IgAN)
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.
- Trial name
- Verdant (NCT07773727)
- Testing
- ARGX-121
- Where
- 11 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- argenx
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
IgAN, IgAVN
Study of Ravulizumab in Pediatric Participants With Primary IgAN
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or…
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis
- Trial name
- NCT07024563
- Testing
- Ravulizumab
- Where
- 15 sites in United States, China and 5 more
- Volunteers
- 36 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgAN
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients.
- Trial name
- NCT07606352
- Testing
- STL303
- Where
- 8 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Sitala Bio LTD